BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1532 related articles for article (PubMed ID: 34000769)

  • 21. [Real-world data analysis of 3012 patients undergoing laparoscopic radical gastrectomy in a single center over the past 12 years].
    Wang LJ; Li Z; Wang S; Liu HD; Li QY; Li BW; Xu JH; Ge H; Wang WZ; Li FY; He ZY; Zhang DC; Xu H; Yang L; Xu ZK
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Aug; 25(8):716-725. PubMed ID: 35970806
    [No Abstract]   [Full Text] [Related]  

  • 22. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
    He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
    World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study.
    Zhao L; Fu Y; Niu P; Zhang F; Jiao F; Zhou X; Wu Z; Wang W; Luan X; Han X; He M; Guan Q; Li Y; Zhao D; Gao J; Chen Y
    Oncologist; 2023 Oct; 28(10):e891-e901. PubMed ID: 37104872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis.
    Stumpf PK; Amini A; Jones BL; Koshy M; Sher DJ; Lieu CH; Schefter TE; Goodman KA; Rusthoven CG
    Cancer; 2017 Sep; 123(17):3402-3409. PubMed ID: 28513823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prognostic analysis of different comprehensive treatment models for locally advanced esophageal squamous cell carcinoma based on propensity score matching].
    Wang YC; Liu JF; Lu H; Zhang XR; Sun XS
    Zhonghua Wai Ke Za Zhi; 2022 Jan; 60(1):79-83. PubMed ID: 34954951
    [No Abstract]   [Full Text] [Related]  

  • 26. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
    Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
    BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
    Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
    [No Abstract]   [Full Text] [Related]  

  • 28. Does hipec improve outcomes in gastric cancer patients treated with perioperative chemotherapy and radical surgery? A propensity-score matched analysis.
    Diniz TP; da Costa WL; Fonseca de Jesus VH; Ribeiro HSC; Diniz AL; de Godoy AL; de Farias IC; Torres SM; Felismino TC; Coimbra FJF
    J Surg Oncol; 2020 Apr; 121(5):823-832. PubMed ID: 31950511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
    Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Surgical treatment and prognosis of Borrmann type IIII( gastric cancer involving the whole stomach].
    Dong R; Zhang Z; Zhou Y; Hua Y; Guo J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Feb; 21(2):185-189. PubMed ID: 29492918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of clinicopathological characteristics and prognosis on 42 patients with primary gastric adenosquamous cell carcinoma].
    Li B; Sun L; Wang X; Deng J; Ding X; Wang X; Ke B; Zhang L; Zhang R; Liang H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Feb; 20(2):207-212. PubMed ID: 28226357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience.
    Ghidini M; Donida BM; Totaro L; Ratti M; Pizzo C; Benzoni I; Lomiento D; Aldighieri F; Toppo L; Ranieri V; Senti C; Tanzi G; Martinotti M; Passalacqua R; Rovatti M; Tomasello G
    Clin Transl Oncol; 2020 Jul; 22(7):1004-1012. PubMed ID: 31599376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
    Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
    JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Value of preoperative abdominal contrast-enhanced multiple-row detector computed tomography in predicting the postoperative 1-year disease-free survival for gastric cancer].
    Feng C; Cheng J; Xiang H; Hong N; Ye Y; Wang Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1059-1064. PubMed ID: 30269328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.
    Feng D; Leong M; Li T; Chen L; Li T
    World J Surg Oncol; 2015 Jan; 13():11. PubMed ID: 25634099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving survival of stage II-III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy.
    Li Y; Zhu Z; Ma F; Xue L; Tian Y
    Cancer Med; 2020 Sep; 9(18):6617-6628. PubMed ID: 32744431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.
    Ruf C; Thomusch O; Goos M; Makowiec F; Illerhaus G; Ruf G
    BMC Surg; 2014 Jan; 14():5. PubMed ID: 24461063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
    Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
    BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?
    Reddavid R; Sofia S; Chiaro P; Colli F; Trapani R; Esposito L; Solej M; Degiuli M
    World J Gastroenterol; 2018 Jan; 24(2):274-289. PubMed ID: 29375213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 77.